Page 8 - Final Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AbbVie to Showcase Breadth of Oncology Portfolio and Pipeline at the 2021 ASCO and EHA Annual Congresses ABBVie will present results from 43 abstracts across 12 types of cancer during the upcoming virtual American Society of Clinical Oncology Annual Meeting and the virtual European Hematology Association congress . “We are advancing discovery and innovation to improve on the standards of care for blood cancer treatment,” said Mohamed Zaki M.D., Ph.D., vice president and global head of oncology development, AbbVie. “We … – ABBVie (NYSE: ABBV) will present results from 43 abstracts...

Novavax's COVID Vaccine Found Effective in Final Trial Analysis by Angela Mohan on  March 12, 2021 at 2:31 PM Novavax's COVID-19 shot found to be 96.4% effective against mild, moderate and severe symptoms of COVID-19 in the final analysis of a late-stage trial in the U.K. The vaccine would be produced at eight locations including the Serum Institute of India, with which Novavax has an agreement to produce around 2 billion doses a year. The analysis showed the vaccine had 86.3 percent efficacy against the UK variant B.1.1.7/501Y.V1 but it was only 55.4 percent against the So...

March 12, 2021 6:08 AM By Brandon Lee President Joe Biden offered Americans a glimpse of hope that life would begin to return to normal this summer as he marked a year of U.S. shutdowns and death, ordering a further acceleration of the government’s efforts to end the pandemic. In his first prime-time address to the country since his inauguration, the president directed states to make all U.S. adults eligible for vaccinations by May 1, and he said his administration would reach his goal of 100 million shots in his first 100 days in office by his 60th day as president. “We...

Data from 25,800 participants in Phase 3 trial in India, received vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated and demonstrated 81% efficacy in preventing COVID-19 in those without prior infection after the second dose.Clinical trial to continue through to final analysis at 130 confirmed cases in order to gather further data and to evaluate the efficacy of COVAXIN in additional secondary study endpoints. MALVERN, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comm...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis Erytech Pharma S.A.February 8, 2021 GMT ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis                                                         The Independent Data Monitoring Committee (IDMC) recommends trial to continue to final analysis, expected in Q4 2021 No safety issues identified, consistent...